More about

Car T-Cell Therapy

News
March 01, 2022
3 min read
Save

FDA approves Carvykti as second CAR T-cell therapy for advanced multiple myeloma

FDA approves Carvykti as second CAR T-cell therapy for advanced multiple myeloma

The FDA approved ciltacabtagene autoleucel, a chimeric antigen receptor T-cell therapy for treatment of adults with relapsed or refractory multiple myeloma.

News
February 28, 2022
4 min read
Save

Questions remain about best front-line treatment in mantle cell lymphoma

As new therapeutic options for mantle cell lymphoma emerge, physicians are learning where they best fit into the treatment armamentarium.

News
February 28, 2022
3 min read
Save

Researchers develop test to predict durable remissions after CAR-T for lymphoma

Researchers develop test to predict durable remissions after CAR-T for lymphoma

Researchers have developed a novel quantitative assay that can predict which patients will achieve durable remissions after CD19-directed chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma.

News
February 21, 2022
3 min read
Save

Nonviral CAR-T is ‘remarkably safe’ and clinically active in B-cell ALL

Nonviral CAR-T is ‘remarkably safe’ and clinically active in B-cell ALL

More than 60% of patients with relapsed or refractory B-cell acute lymphoblastic leukemia achieved initial complete remission after receiving an investigational chimeric antigen receptor T-cell therapy, phase 1/phase 2 study results showed.

News
February 21, 2022
1 min read
Save

Memorial Sloan Kettering pauses CAR-T clinical trial to investigate patient death

Memorial Sloan Kettering pauses CAR-T clinical trial to investigate patient death

Memorial Sloan Kettering Cancer Center placed a pause on a phase 1 clinical trial of ATA2271 — a chimeric antigen receptor T-cell therapy — after one patient treated with the investigational therapy died.

News
February 17, 2022
1 min read
Save

FDA grants priority review to Breyanzi for second-line treatment of large B-cell lymphoma

FDA grants priority review to Breyanzi for second-line treatment of large B-cell lymphoma

The FDA granted priority review to lisocabtagene maraleucel as second-line treatment of adults with relapsed or refractory large B-cell lymphoma.

News
February 17, 2022
1 min read
Save

FDA places clinical hold on Legend Biotech’s CAR-T for T-cell lymphoma

FDA places clinical hold on Legend Biotech’s CAR-T for T-cell lymphoma

The FDA placed a clinical hold on a phase 1 trial of LB1901, a chimeric antigen receptor T-cell therapy for treatment of adults with relapsed or refractory T-cell lymphoma.

News
February 16, 2022
1 min read
Save

FDA grants orphan drug designation to humanized CAR-T for advanced multiple myeloma

FDA grants orphan drug designation to humanized CAR-T for advanced multiple myeloma

The FDA granted orphan drug designation to CT103A, a chimeric antigen receptor T-cell therapy in development for adults with relapsed or refractory multiple myeloma.

News
February 16, 2022
3 min read
Save

Axi-cel CAR-T significantly improves EFS among older patients with non-Hodgkin lymphoma

Axi-cel CAR-T significantly improves EFS among older patients with non-Hodgkin lymphoma

Second-line therapy with axicabtagene ciloleucel conferred a greater than eightfold increase in median EFS compared with standard-of-care treatment for older patients with diffuse large B-cell lymphoma, according to phase 3 study results.

News
February 14, 2022
12 min read
Save

CAR-T poised to create ‘paradigm shift’ in non-Hodgkin lymphoma

CAR-T poised to create ‘paradigm shift’ in non-Hodgkin lymphoma

Since the approval of the first chimeric antigen receptor T-cell therapy, the research community has grappled with a crucial question.

View more